Please login to the form below

Not currently logged in
Email:
Password:

Former Quintiles president Jeff Thomis to chair Idis

Will oversee company’s activities to develop managed access programmes for medicines

Idis Jeff ThomisIdis has appointed Jeff Thomis as chairman to oversee the company's activities in creating managed access programmes for medicines.

The appointment marks a change of direction for Thomis, who has spent a large part of his career in the management of clinical trials.

This includes 11 years at clinical research organisation (CRO) Quintiles, which he joined in 1998 as president clinical development Europe before being appointed as president of global clinical development services in 2006.

In his new role, Thomis will work with the board of Idis and its leadership team to develop programmes for pharma and biotech companies to provide unapproved medicines to patients with unmet medical needs.

“As specialists in the field, Idis is strongly placed to deliver highly effective solutions to our customers who include pharmaceutical and biotech companies, healthcare professionals and patients,” said Thomis.

Prior to his time at Quintiles, Thomis was director of infectious diseases at Bristol-Myers Squibb.

6th September 2013

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

Patient engagement
Taking a holistic approach to patient care
The importance of recognising each patient as an individual...
The concordance conundrum – the tech divide
“Hello? Can you hear me? I think you are on mute” – how many times have we all heard this over the past five or so months? Not exactly the...
3 ways to increase patient retention rates in clinical trials
Retention rates are falling in clinical trials. Yes, it is a bit disheartening. But there are some straightforward things you can do to turn it around....

Infographics